rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Medtronic Spinal and Biologics
ClinicalTrials.gov Identifier:
NCT00707265
First received: June 26, 2008
Last updated: August 1, 2013
Last verified: September 2011
  Purpose

The purpose of this study was to evaluate the rhBMP-2/CRM/CD HORIZON® Spinal System as a method of facilitating spinal fusion in patients with degenerative disc disease.


Condition Intervention Phase
Degenerative Disc Disease
Device: rhBMP-2/CRM/CD HORIZON® Spinal System
Device: Autograft/CD HORIZON® Spinal System
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Randomized Clinical Investigation of rhBMP-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease

Further study details as provided by Medtronic Spinal and Biologics:

Primary Outcome Measures:
  • Overall Success [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]

    A patient will be considered an overall success if all of the following conditions are met:

    1. fusion;
    2. pain/disability (Oswestry) improvement;
    3. maintenance or improvement in neurological status;
    4. no serious adverse event classified as implant associated or implant/surgical procedure associated;
    5. no additional surgical procedure classified as a "failure."


Secondary Outcome Measures:
  • Fusion [ Time Frame: 24 months ] [ Designated as safety issue: No ]

    Fusion is defined as:

    1. Evidence of bridging trabecular bone.
    2. No evidence of motion.
    3. Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass.

  • Pain/Disability Status [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    The self-administered Oswestry Low Back Pain Disability Questionnaire will be used. Success will be defined as pain/disability improvement postoperatively according to the definition: Preoperative Score - Postoperative Score >= 15 points

  • Overall Neurological Status [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Neurological status will be assessed preoperatively and postoperatively using a neurological status scale. Neurological status is based on four types of measurements (sections): motor, sensory, reflexes, and straight leg raise. Overall measure of neurological status will be based on success statuses in the four parameters.

  • General Health Status [ Time Frame: 24 months ] [ Designated as safety issue: No ]

    The Medical Outcomes Study 36-item Short Form Health Survey (SF-36) will be used to assess general health status. The SF-36 results can be summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). Success will be defined as a maintenance or improvement in status postoperatively as compared to the preoperative condition. To be classified as a success, the following criteria must be met:

    PCSPostop - PCSPreop >= 0; MCSPostop - MCSPreop >= 0


  • Back Pain [ Time Frame: 24 months ] [ Designated as safety issue: No ]

    Numerical rating scales will be used to evaluate pain intensity and duration. The pain score (0 min, 20 Max) is derived by adding the numerical rating scores from the pain intensity (0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be.") and duration scales (0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time"). Success for back and leg pain is described as follows:

    Preoperative Score - Postoperative Score >=0


  • Leg Pain [ Time Frame: 24 months ] [ Designated as safety issue: No ]

    Numerical rating scales will be used to evaluate pain intensity and duration. The pain score (0 min, 20 Max) is derived by adding the numerical rating scores from the pain intensity (0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be.") and duration scales (0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time"). Success for back and leg pain is described as follows:

    Preoperative Score - Postoperative Score >=0


  • Operative Time [ Time Frame: At the time of operation ] [ Designated as safety issue: No ]
  • Blood Loss [ Time Frame: At the time of operation ] [ Designated as safety issue: No ]
  • Hospital Days [ Time Frame: At the time of discharge ] [ Designated as safety issue: No ]

Enrollment: 463
Study Start Date: March 2002
Study Completion Date: February 2010
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Investigational
Open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System.
Device: rhBMP-2/CRM/CD HORIZON® Spinal System

The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.

The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used.

Other Names:
  • rhBMP-2
  • CRM
  • CD HORIZON® Spinal System
Active Comparator: Control
The bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.
Device: Autograft/CD HORIZON® Spinal System
The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
Other Names:
  • Autograft
  • CD HORIZON® Spinal System

Detailed Description:

This clinical trial was conducted to evaluate the rhBMP-2/CRM/CD HORIZON® Spinal System for posterolateral fusion treatment of patients with symptomatic degenerative disc disease versus the control group of autogenous bone with the CD HORIZON® Spinal System.

The investigational treatment was the open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System. One investigational implant was placed across two adjacent transverse processes on each side of the spine during the spinal fusion procedure.

The control treatment was the bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Each patient participating in this clinical trial must meet all of the following inclusion criteria:

  1. Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history of pain and radiographic studies:
  2. Requires fusion of a single level disc space from L1 to S1.
  3. Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of 6 months.
  4. If of child-bearing potential, patient is non-pregnant, non-nursing, and agrees to use adequate contraception for 1 year following surgery.

Exclusion Criteria:

A patient meeting any of the following criteria is to be excluded from this clinical trial:

  1. Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade 1 or less spondylolisthesis at the involved level.
  2. Had previous spinal fusion surgical procedure at the involved level.
  3. Requires spinal fusion at more than one lumbar level.
  4. Has been previously diagnosed with osteopenia.
  5. Has presence of active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).
  6. Has a history of autoimmune disease (e.g. Systemic Lupus Erythematosus or dermatomyositis).
  7. Has a history of exposure to injectable collagen or silicone implants.
  8. Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP 2/CRM implantation.
  9. Has received any previous exposure to any/all BMP's of either human or animal extraction.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00707265

  Show 28 Study Locations
Sponsors and Collaborators
Medtronic Spinal and Biologics
Investigators
Principal Investigator: Kenneth Burkus, MD The Hughston Clinic, P.C.
Principal Investigator: John Dimar, MD Spine Institute
  More Information

No publications provided

Responsible Party: Medtronic Spinal and Biologics
ClinicalTrials.gov Identifier: NCT00707265     History of Changes
Other Study ID Numbers: P01-05
Study First Received: June 26, 2008
Last Updated: August 1, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Intervertebral Disc Degeneration
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on September 16, 2014